The global portable oxygen concentrators market is poised for robust expansion, with its valuation expected to rise from USD 2.18 billion in 2026 to USD 3.24 billion by 2031, registering a compound annual growth rate (CAGR) of 8.28% over the forecast period. According to the latest analysis by Mordor Intelligence, device miniaturization, higher-density batteries, and broader reimbursement for home oxygen therapy are sustaining strong demand even after the acute phase of the COVID-19 pandemic.
The market received a significant shakeup following Philips Respironics’ withdrawal of two major models in 2024, which opened capacity for rivals and accelerated production scale-ups at companies such as Drive DeVilbiss Healthcare and GCE Group. Continuous flow technology accounted for 53.20% of market share in 2025, remaining the dominant prescription choice for severe hypoxemia. However, pulse flow devices are growing at a faster 9.29% CAGR, driven by lighter form factors, longer runtimes, and smarter breath-detection algorithms that appeal to active users.
By application, chronic obstructive pulmonary disease (COPD) commanded 62.10% of the market in 2025, anchoring demand due to well-established long-term therapy protocols. Meanwhile, respiratory distress syndrome is projected to post the fastest CAGR of 9.88% through 2031, as clinicians extend portable therapy into post-acute recovery for post-COVID fibrosis and other conditions. Home-care settings represented 57.35% of revenue in 2025 and continue to be the primary growth engine, supported by payer preference for home-based care and patient autonomy. Over 1.5 million U.S. adults currently rely on supplemental oxygen.
In distribution channels, durable medical equipment (DME) stores led with 43.80% share in 2025, but direct-to-consumer e-commerce is disrupting the status quo, forecast to climb at an 11.16% CAGR. Secure online portals now connect prescriptions directly to manufacturer warehouses, cutting lead times and enabling rapid claims processing.
Geographically, North America contributed the largest revenue share (43.25%) in 2025, buoyed by predictable Medicare payment policies and comprehensive FAA rules that allow approved devices for inflight use. The Asia-Pacific region is the fastest-growing market, expected to register an 11.02% CAGR through 2031. China and India are simplifying medical device registration and investing in local production capacity. Japan leads early adoption of miniaturized devices for its aging population.
Key drivers include the rising prevalence of chronic respiratory diseases (affecting an estimated 213 million people globally), aging demographics, and post-COVID home-based oxygen therapy demand. However, the market faces restraints such as import tariffs on lithium-ion cells – the U.S. has imposed duties of up to 125% on Chinese goods, affecting many battery packs – and the proliferation of counterfeit low-cost devices that erode brand trust. Recent FDA warning letters to Shenzhen Moyeah and LEEL Tech highlight ongoing regulatory efforts to combat unapproved products.
Competitive leaders include Inogen, Drive DeVilbiss Healthcare, CAIRE (Chart Industries), ResMed, and Invacare. Recent developments include Inogen’s USD 27.2 million investment for a 9.9% stake in Yuwell in February 2025 to expand Asia-Pacific reach, and the launch of the Inogen Rove 4 in October 2024 – a sub-3-pound portable concentrator delivering up to 840 ml/min. Overall, the portable oxygen concentrators market is set for sustained growth, driven by technology advances, home healthcare trends, and expanding applications beyond traditional COPD care.
Source: Mordor Intelligence – Global Portable Oxygen Concentrators Market Report (2026-2031)